The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs...

|About: Abbott Laboratories (ABT)|By:, SA News Editor

The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)